Holen Sie sich die Stockscreener-App
11.54
3.68%
0.41
Vorhandelsmarkt:
11.48
-0.06
-0.52%
Schlusskurs vom Vortag:
$11.13
Offen:
$11.22
24-Stunden-Volumen:
2.81M
Relative Volume:
0.82
Marktkapitalisierung:
$900.80M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-12.54
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
+4.43%
1M Leistung:
+1.76%
6M Leistung:
+23.03%
1J Leistung:
+15.52%
1-Tages-Spanne:
$10.87
$11.55
1-Wochen-Bereich:
$10.87
$11.90
52-Wochen-Spanne:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
11.54 | 872.03M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Is CorMedix Inc. stock positioned for digital transformationWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
Is CorMedix Inc. (19KA) stock protected from inflation2025 Earnings Impact & Expert Approved Momentum Trade Ideas - newser.com
What institutional flow reveals about CorMedix Inc.Take Profit & Verified Swing Trading Watchlist - newser.com
What drives CorMedix Inc 19KA stock priceBreakout Stock Watch & Free Trend Following Techniques - earlytimes.in
Will CorMedix Inc. stock outperform Nasdaq indexJuly 2025 Retail & Technical Pattern Alert System - newser.com
Will CorMedix Inc. stock benefit from green energy trendsDividend Hike & Low Risk Investment Opportunities - newser.com
Advanced analytics toolkit walkthrough for CorMedix Inc.2025 Valuation Update & Stepwise Entry and Exit Trade Signals - newser.com
Using economic indicators to assess CorMedix Inc. potentialOil Prices & Weekly Watchlist of Top Performers - newser.com
Will CorMedix Inc. (19KA) stock beat Nasdaq index returnsGap Down & Fast Entry and Exit Trade Plans - newser.com
Will CorMedix Inc. (19KA) stock profit from AI boomWeekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Why CorMedix Inc. (19KA) stock appeals to dividend investorsJuly 2025 Earnings & Verified High Yield Trade Plans - newser.com
Is CorMedix Inc. reversing from oversold territoryMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
Visual analytics tools that track CorMedix Inc. performanceWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Trend analysis for CorMedix Inc. this weekMarket Movement Recap & AI Powered Market Entry Strategies - newser.com
Can CorMedix Inc. stock weather global recessionJuly 2025 Technicals & Verified Swing Trading Watchlists - newser.com
Could the FDA Approval Spark a New Chapter for CorMedix in 2025? - Yahoo Finance
Should I hold or sell CorMedix Inc. stock in 20252025 Volume Leaders & Real-Time Volume Analysis - newser.com
Applying chart zones and confluence areas to CorMedix Inc.Weekly Profit Report & Verified Entry Point Detection - newser.com
Is CorMedix Inc. (19KA) stock a buy for dividend portfoliosMarket Risk Summary & Expert Verified Movement Alerts - newser.com
Will CorMedix Inc. stock recover faster than market2025 Investor Takeaways & Short-Term Trading Alerts - newser.com
Can CorMedix Inc. stock deliver surprise earnings beat2025 Dividend Review & Consistent Return Strategy Ideas - newser.com
Reversal indicators forming on CorMedix Inc. stock2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Is CorMedix Inc. stock safe for conservative investorsAnalyst Upgrade & Stepwise Trade Execution Plans - newser.com
Visualizing CorMedix Inc. stock with heatmapsRisk Management & Fast Moving Market Watchlists - newser.com
Will CorMedix Inc. stock sustain high P E ratios2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
CRMD6219746 Bond Coupon Analysis — Rate & Payments - TradingView
Understanding CorMedix Inc.’s price movementMarket Growth Report & Long-Term Capital Growth Ideas - newser.com
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 - The Globe and Mail
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 - Quiver Quantitative
CorMedix (NASDAQ: CRMD) to report Q3 results; 8:30 a.m. ET call before market open - Stock Titan
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):